207 related articles for article (PubMed ID: 21552322)
1. ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1.
Dunbier AK; Anderson H; Ghazoui Z; Lopez-Knowles E; Pancholi S; Ribas R; Drury S; Sidhu K; Leary A; Martin LA; Dowsett M
PLoS Genet; 2011 Apr; 7(4):e1001382. PubMed ID: 21552322
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues.
Shenker NS; Flower KJ; Wilhelm-Benartzi CS; Dai W; Bell E; Gore E; El Bahrawy M; Weaver G; Brown R; Flanagan JM
BMC Cancer; 2015 May; 15():337. PubMed ID: 25927974
[TBL] [Abstract][Full Text] [Related]
3. C6ORF97-ESR1 breast cancer susceptibility locus: influence on progression and survival in breast cancer patients.
Yamamoto-Ibusuki M; Yamamoto Y; Fujiwara S; Sueta A; Yamamoto S; Hayashi M; Tomiguchi M; Takeshita T; Iwase H
Eur J Hum Genet; 2015 Jul; 23(7):949-56. PubMed ID: 25370037
[TBL] [Abstract][Full Text] [Related]
4. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K
Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221
[TBL] [Abstract][Full Text] [Related]
5. Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors.
Leal MF; Haynes BP; Schuster E; Yeo B; Afentakis M; Zabaglo L; Martins V; Buus R; Dodson A; Cheang MCU; Smith IE; Martin LA; Dowsett M
Clin Cancer Res; 2019 Dec; 25(24):7485-7496. PubMed ID: 31548345
[TBL] [Abstract][Full Text] [Related]
6. Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer.
Li Y; Li Y; Wedrén S; Li G; Charn TH; Desai KV; Bonnard C; Czene K; Humphreys K; Darabi H; Einarsdóttir K; Heikkinen T; Aittomäki K; Blomqvist C; Chia KS; Nevanlinna H; Hall P; Liu ET; Liu J
Breast Cancer Res; 2011 Jan; 13(1):R10. PubMed ID: 21269472
[TBL] [Abstract][Full Text] [Related]
7. Aromatase promoter I.f is regulated by estrogen receptor alpha (ESR1) in mouse hypothalamic neuronal cell lines.
Yilmaz MB; Wolfe A; Cheng YH; Glidewell-Kenney C; Jameson JL; Bulun SE
Biol Reprod; 2009 Nov; 81(5):956-65. PubMed ID: 19605792
[TBL] [Abstract][Full Text] [Related]
8. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
9. Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors.
Muthukaruppan A; Lasham A; Woad KJ; Black MA; Blenkiron C; Miller LD; Harris G; McCarthy N; Findlay MP; Shelling AN; Print CG
Clin Breast Cancer; 2017 Apr; 17(2):139-153. PubMed ID: 27756582
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
11. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
12. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers.
Veeraraghavan J; Tan Y; Cao XX; Kim JA; Wang X; Chamness GC; Maiti SN; Cooper LJ; Edwards DP; Contreras A; Hilsenbeck SG; Chang EC; Schiff R; Wang XS
Nat Commun; 2014 Aug; 5():4577. PubMed ID: 25099679
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.
Dunning AM; Michailidou K; Kuchenbaecker KB; Thompson D; French JD; Beesley J; Healey CS; Kar S; Pooley KA; Lopez-Knowles E; Dicks E; Barrowdale D; Sinnott-Armstrong NA; Sallari RC; Hillman KM; Kaufmann S; Sivakumaran H; Moradi Marjaneh M; Lee JS; Hills M; Jarosz M; Drury S; Canisius S; Bolla MK; Dennis J; Wang Q; Hopper JL; Southey MC; Broeks A; Schmidt MK; Lophatananon A; Muir K; Beckmann MW; Fasching PA; Dos-Santos-Silva I; Peto J; Sawyer EJ; Tomlinson I; Burwinkel B; Marme F; Guénel P; Truong T; Bojesen SE; Flyger H; González-Neira A; Perez JI; Anton-Culver H; Eunjung L; Arndt V; Brenner H; Meindl A; Schmutzler RK; Brauch H; Hamann U; Aittomäki K; Blomqvist C; Ito H; Matsuo K; Bogdanova N; Dörk T; Lindblom A; Margolin S; Kosma VM; Mannermaa A; Tseng CC; Wu AH; Lambrechts D; Wildiers H; Chang-Claude J; Rudolph A; Peterlongo P; Radice P; Olson JE; Giles GG; Milne RL; Haiman CA; Henderson BE; Goldberg MS; Teo SH; Yip CH; Nord S; Borresen-Dale AL; Kristensen V; Long J; Zheng W; Pylkäs K; Winqvist R; Andrulis IL; Knight JA; Devilee P; Seynaeve C; Figueroa J; Sherman ME; Czene K; Darabi H; Hollestelle A; van den Ouweland AM; Humphreys K; Gao YT; Shu XO; Cox A; Cross SS; Blot W; Cai Q; Ghoussaini M; Perkins BJ; Shah M; Choi JY; Kang D; Lee SC; Hartman M; Kabisch M; Torres D; Jakubowska A; Lubinski J; Brennan P; Sangrajrang S; Ambrosone CB; Toland AE; Shen CY; Wu PE; Orr N; Swerdlow A; McGuffog L; Healey S; Lee A; Kapuscinski M; John EM; Terry MB; Daly MB; Goldgar DE; Buys SS; Janavicius R; Tihomirova L; Tung N; Dorfling CM; van Rensburg EJ; Neuhausen SL; Ejlertsen B; Hansen TV; Osorio A; Benitez J; Rando R; Weitzel JN; Bonanni B; Peissel B; Manoukian S; Papi L; Ottini L; Konstantopoulou I; Apostolou P; Garber J; Rashid MU; Frost D; ; Izatt L; Ellis S; Godwin AK; Arnold N; Niederacher D; Rhiem K; Bogdanova-Markov N; Sagne C; Stoppa-Lyonnet D; Damiola F; ; Sinilnikova OM; Mazoyer S; Isaacs C; Claes KB; De Leeneer K; de la Hoya M; Caldes T; Nevanlinna H; Khan S; Mensenkamp AR; ; Hooning MJ; Rookus MA; Kwong A; Olah E; Diez O; Brunet J; Pujana MA; Gronwald J; Huzarski T; Barkardottir RB; Laframboise R; Soucy P; Montagna M; Agata S; Teixeira MR; ; Park SK; Lindor N; Couch FJ; Tischkowitz M; Foretova L; Vijai J; Offit K; Singer CF; Rappaport C; Phelan CM; Greene MH; Mai PL; Rennert G; Imyanitov EN; Hulick PJ; Phillips KA; Piedmonte M; Mulligan AM; Glendon G; Bojesen A; Thomassen M; Caligo MA; Yoon SY; Friedman E; Laitman Y; Borg A; von Wachenfeldt A; Ehrencrona H; Rantala J; Olopade OI; Ganz PA; Nussbaum RL; Gayther SA; Nathanson KL; Domchek SM; Arun BK; Mitchell G; Karlan BY; Lester J; Maskarinec G; Woolcott C; Scott C; Stone J; Apicella C; Tamimi R; Luben R; Khaw KT; Helland Å; Haakensen V; Dowsett M; Pharoah PD; Simard J; Hall P; García-Closas M; Vachon C; Chenevix-Trench G; Antoniou AC; Easton DF; Edwards SL
Nat Genet; 2016 Apr; 48(4):374-86. PubMed ID: 26928228
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients.
Tomita S; Zhang Z; Nakano M; Ibusuki M; Kawazoe T; Yamamoto Y; Iwase H
Cancer Sci; 2009 Jun; 100(6):1012-7. PubMed ID: 19320640
[TBL] [Abstract][Full Text] [Related]
15. PSF Promotes ER-Positive Breast Cancer Progression via Posttranscriptional Regulation of
Mitobe Y; Iino K; Takayama KI; Ikeda K; Suzuki T; Aogi K; Kawabata H; Suzuki Y; Horie-Inoue K; Inoue S
Cancer Res; 2020 Jun; 80(11):2230-2242. PubMed ID: 32213542
[TBL] [Abstract][Full Text] [Related]
16. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer.
Madhu Krishna B; Chaudhary S; Mishra DR; Naik SK; Suklabaidya S; Adhya AK; Mishra SK
BMC Cancer; 2018 May; 18(1):607. PubMed ID: 29843638
[TBL] [Abstract][Full Text] [Related]
18. Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.
Teinturier R; Abou Ziki R; Kassem L; Luo Y; Malbeteau L; Gherardi S; Corbo L; Bertolino P; Bachelot T; Treilleux I; Zhang CX; Le Romancer M
Breast Cancer Res Treat; 2021 Dec; 190(3):389-401. PubMed ID: 34561764
[TBL] [Abstract][Full Text] [Related]
19. Admixture mapping identifies a locus on 6q25 associated with breast cancer risk in US Latinas.
Fejerman L; Chen GK; Eng C; Huntsman S; Hu D; Williams A; Pasaniuc B; John EM; Via M; Gignoux C; Ingles S; Monroe KR; Kolonel LN; Torres-Mejía G; Pérez-Stable EJ; Burchard EG; Henderson BE; Haiman CA; Ziv E
Hum Mol Genet; 2012 Apr; 21(8):1907-17. PubMed ID: 22228098
[TBL] [Abstract][Full Text] [Related]
20. Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha.
Lin W; Huang J; Liao X; Yuan Z; Feng S; Xie Y; Ma W
Pharmacol Res; 2016 Sep; 111():849-858. PubMed ID: 27491559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
